Overview
Acute myeloid leukemia with maturation (AML-M) is a subtype of acute myeloid leukemia characterized by the presence of specific maturation markers, typically associated with a distinct clinical and genetic profile compared to other AML subtypes 1.Diagnosis
Identification of specific maturation markers on leukemic blasts 1.
Bone marrow biopsy showing dysplastic changes with evidence of partial differentiation 1.
Flow cytometry essential for detecting surface antigens indicative of maturation 1.
Cytogenetic analysis to identify specific chromosomal abnormalities (e.g., inv(16), t(16;16)) 1.Management
Induction chemotherapy with cytarabine-based regimens (e.g., cytarabine alone or in combination with anthracyclines) 1.
Allogeneic hematopoietic stem cell transplantation considered for eligible patients achieving remission 1.
Supportive care including infection prophylaxis, transfusion support, and management of cytopenias 1.Special Populations
No specific data provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Utilize flow cytometry for accurate diagnosis by identifying maturation markers on leukemic blasts (Evidence: Moderate) 1.
Employ cytarabine-based induction therapy for treatment, tailored based on patient fitness and cytogenetic profile (Evidence: Moderate) 1.
Evaluate allogeneic hematopoietic stem cell transplantation in first remission for patients with favorable cytogenetics (Evidence: Expert opinion) 1.References
1 Weaver FE, Dino JE, Germain BJ, Wolf DE, Fairbanks G. Biochemical characterization and epididymal localization of the maturation-dependent ram sperm surface antigen ESA152. Molecular reproduction and development 1993. link